Neuphoria Therapeutics Files Definitive Additional Materials

TL;DR

NEUP filed more proxy docs. Shareholders, pay attention.

AI Summary

Neuphoria Therapeutics Inc. filed definitive additional materials (DEFA14A) on November 25, 2025. This filing relates to proxy statements under Section 14(a) of the Securities Exchange Act of 1934. The company, formerly known as Bionomics Limited, is in the pharmaceutical preparations industry and is listed on NASDAQ under the ticker NEUP.

Why It Matters

This filing indicates that Neuphoria Therapeutics is providing updated or supplementary information to shareholders regarding proxy matters, which could influence voting decisions on corporate actions.

Risk Assessment

Risk Level: low — This filing is a routine regulatory submission for additional proxy materials and does not inherently present new financial or operational risks.

Key Players & Entities

• Neuphoria Therapeutics Inc. (company) — Registrant
• Bionomics Limited (company) — Former company name
• 20251125 (date) — Filing date
• 0001191070 (company) — Central Index Key
• NEUP (ticker) — NASDAQ ticker symbol

FAQ

Key Financial Figures

• $0.6M — hase 3 Enabling NDA Enabling DP SUPPLY ($0.6M) CHRONIC TOXICITY ($2.5 - $ 3 M) MASS B
• $2.5 — ing DP SUPPLY ($0.6M) CHRONIC TOXICITY ($2.5 - $ 3 M) MASS BALANCE STUDY ($2M) CMC C
• $2M — CITY ($2.5 - $ 3 M) MASS BALANCE STUDY ($2M) CMC CARCINOGENICITY ($1.5M+$1.5M) PROC
• $1.5M — ALANCE STUDY ($2M) CMC CARCINOGENICITY ($1.5M+$1.5M) PROCESS DEVELOPMENT/VALIDATION (
• $2 — +$1.5M) PROCESS DEVELOPMENT/VALIDATION ($2+$3M) ABUSE LIABILITY ($2M) Clinical Pha
• $3M — .5M) PROCESS DEVELOPMENT/VALIDATION ($2+$3M) ABUSE LIABILITY ($2M) Clinical Pharmac
• $1M — BILITY ($2M) Clinical Pharmacology DDI ($1M) API + DP SUPPLY ($5M) PTSD Program PTS
• $5M — Pharmacology DDI ($1M) API + DP SUPPLY ($5M) PTSD Program PTSD PHASE 3 (12 - WEEK)
• $25M — PTSD Program PTSD PHASE 3 (12 - WEEK) ($25M) OPEN LABEL SAFETY EXTENSION ($20M) PTS
• $20M — EK) ($25M) OPEN LABEL SAFETY EXTENSION ($20M) PTSD PHASE 2b (8 - WEEK) ($10.5 - 12M)
• $10.5 — ENSION ($20M) PTSD PHASE 2b (8 - WEEK) ($10.5 - 12M) IA & DOSING DECISION QWBA ($0.35
• $0.35M — $10.5 - 12M) IA & DOSING DECISION QWBA ($0.35M) OTHER CLIN PHARM ($5M) 2025 2026 2027
• $10M — ts Payments received: US$20M upfront, US$10M for Phase 1 milestone and US$15M for Ph
• $15M — ont, US$10M for Phase 1 milestone and US$15M for Phase 2 milestone for AD program El
• $450M — AD program Eligible to receive up to US$450M in additional milestone payments plus r

Filing Documents

• ea0267133-defa14a_neuphoria.htm (DEFA14A) — 44KB
• image_001.jpg (GRAPHIC) — 10KB
• image_002.jpg (GRAPHIC) — 702KB
• image_003.jpg (GRAPHIC) — 763KB
• image_004.jpg (GRAPHIC) — 1522KB
• image_005.jpg (GRAPHIC) — 523KB
• image_006.jpg (GRAPHIC) — 349KB
• image_007.jpg (GRAPHIC) — 736KB
• image_008.jpg (GRAPHIC) — 680KB
• image_009.jpg (GRAPHIC) — 604KB
• image_010.jpg (GRAPHIC) — 629KB
• image_011.jpg (GRAPHIC) — 555KB
• image_012.jpg (GRAPHIC) — 435KB
• image_013.jpg (GRAPHIC) — 733KB
• image_014.jpg (GRAPHIC) — 1908KB
• image_015.jpg (GRAPHIC) — 435KB
• image_016.jpg (GRAPHIC) — 702KB
• image_017.jpg (GRAPHIC) — 897KB
• image_018.jpg (GRAPHIC) — 332KB
• image_019.jpg (GRAPHIC) — 837KB
• image_020.jpg (GRAPHIC) — 777KB
• image_021.jpg (GRAPHIC) — 899KB
• image_022.jpg (GRAPHIC) — 694KB
• image_023.jpg (GRAPHIC) — 805KB
• image_024.jpg (GRAPHIC) — 724KB
• image_025.jpg (GRAPHIC) — 689KB
• image_026.jpg (GRAPHIC) — 512KB
• 0001213900-25-114764.txt ( ) — 25457KB

From the Filing

ADDITIONAL MATERIALS U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant Filed by a Party other than the Registrant   Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive Proxy Statement Definitive Additional Materials Soliciting Material under §240. Rule 14a-12 Neuphoria Therapeutics Inc. (Name of Registrant as Specified in its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check all boxes that apply): No fee required Fee paid previously with preliminary materials Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11 NASDAQ: NEUP / Neuphoria cautions that statements included in this presentation that are not a description of historical facts are forward - looking state ments. Words such as "may," "could," "will," "would," "should," "expect," "plan," "anticipate," "believe," "estimate," "intend," "pr edi ct," "seek," "contemplate," "potential," "continue" or "project" or the negative of these terms or other comparable terminology are intend ed to identify forward - looking statements. The forward - looking statements are based on our current beliefs and expectations. The inclusion of f orward - looking statements should not be regarded as a representation by Neuphoria that any of its plans will be achieved. Actual results may differ materially from those set forth in this presentation due to the risks and uncertainties inherent in the Company's business an d o ther risks described in the Company's filings with the SEC, including the Company's Annual Report on Form 10 - K filed with the SEC, and its other reports. Investors are cautioned not to place undue reliance on these forward - looking statements, which speak only as of the date hereof, and Neuphoria undertakes no obligation to revise or update this presentation to reflect events or circumstances after the date he reo f. Further information regarding these and other risks, uncertainties and other factors is included in Neuphoria's filings with the SEC, copies of which are available from the SEC's website ( www.sec.gov ) and on Neuphoria's website ( www.neuphoriatx.com ) under the heading "Investor Center." All forward - looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe har bor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995. Neuphoria expressly disclaims all liability in respect to actions taken or not taken based on any or all the contents of this presentation. Forward - Looking Statements / By focusing on novel approaches and advancing scientific understanding, we aim to deliver medicines that offer lasting relief and hope for a brighter, healthier future. / Neuphoria's Pipeline INTERNAL PARTNERED PRECLINICAL PROGRAM INDICATION DISCOVERY PRE - CLINICAL PHASE 1 PHASE 2 PHASE 3 NAM : Negative Allosteric Modulator; PAM : Positive Allosteric Modulator; ADHD : Attention Deficit Hyperactivity Disorder; CIAS : Cognitive impairment associated with schizophrenia Post - Traumatic Stress Disorder (PTSD) 7 receptor NAM BNC210 Alzheimer's Disease (AD) Other (CIAS, ADHD) S olid tumors 7 receptor PAM MK - 1167 LGR5 stem cell antigen NextGen 7 receptor NAM Kv3.1/3.2 Agonists = Fast Trac k Development Multiple CNS Indications Cognitive Disorders / BNC210 (soclenicant) Program Overview / BNC210: A Transformative Treatment for PTSD A First - in - Class 7 Nicotinic Receptor Small Molecule Negative Allosteric Modulator (NAM) Novel MoA Unique and differentiated MoA with high confidence in rationale and probabilities of success* Game - changing Product Profile Multiple symptom relief without GABAergic side effects Non - sedating, non - habit forming, not cognition impairing* Large Market Opportunities & Strong IP 9M adults with PTSD each year Blockbuster peak sales IP protection 2040+ Reduction of PTSD symptom severity – clinically significant effects in multiple symptoms Only non - psychedelic novel MoA program in late - stage development *Profile based on a safety and efficacy database of ~800 subjects. MoA = mechanism of action; PTSD = Post - Traumatic Stress Disorder. / Avoiding trauma - related: People Places Activities Nightmares Problems concentrating Sleep disturbances Irritability Aggression Social withdrawal Negative perception of self and world Repetitive unwanted memories Flashbacks Ph2b PTSD data – Thought Intrusions Cluster Enhanced conditioned fear extinction in rodents E motional recovery in humans following a panic attack* Ph2b PTSD data – MADRS and Mood and Cognitions Cluster Antidepressant effects in rodent model of depression Threat avoidance behavior in humans and

View Full Filing

View this DEFA14A filing on SEC EDGAR